We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03564691
Title Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | POL | ISR | GRC | FRA | ESP | CAN | AUS

Facility Status City State Zip Country Details
University of California at San Francisco ( Site 0004) San Francisco California 94158 United States Details
Henry Ford Health System ( Site 0002) Detroit Michigan 48202 United States Details
Washington University ( Site 0003) Saint Louis Missouri 63110 United States Details
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005) Hackensack New Jersey 07601 United States Details
Laura and Isaac Perlmutter Cancer Center ( Site 0008) New York New York 10016 United States Details
Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 00 Columbus Ohio 43210 United States Details
South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001) San Antonio Texas 78229 United States Details
Utah Cancer Specialists ( Site 0011) Salt Lake City Utah 84106 United States Details
Seattle Cancer Care Alliance ( Site 0010) Seattle Washington 98109 United States Details
Liverpool Hospital-Medical Oncology ( Site 0250) Liverpool New South Wales 2170 Australia Details
Princess Alexandra Hospital ( Site 0253) Brisbane Queensland 4102 Australia Details
Juravinski Cancer Centre ( Site 0034) Hamilton Ontario L8V 5C2 Canada Details
The Ottawa Hospital ( Site 0031) Ottawa Ontario K1H 8L6 Canada Details
Princess Margaret Cancer Centre ( Site 0033) Toronto Ontario M5G 2M9 Canada Details
The First Hospital of Jilin University ( Site 0803) Changchun Jilin 130021 China Details
Shanghai Chest Hospital-Oncology department ( Site 0801) Shanghai Shanghai 200030 China Details
West China Hospital of Sichuan University ( Site 0804) Chengdu Sichuan 610041 China Details
Hôpital Européen Georges Pompidou ( Site 2003) Paris Ile-de-France 75015 France Details
Centre Oscar Lambret ( Site 2002) Lille Nord 59000 France Details
Centre Hospitalier Universitaire de Poitiers ( Site 2000) Poitiers Vienne 86000 France Details
University General Hospital of Heraklion ( Site 0110) Heraklion Irakleio 711 10 Greece Details
Euromedica General Clinic of Thessaloniki-Oncology Unit ( Site 0112) Thessaloniki 546 45 Greece Details
European Interbalkan Medical Center ( Site 0111) Thessaloniki 57001 Greece Details
Rambam Health Care Campus-Oncology Division ( Site 0042) Haifa 3109601 Israel Details
Rabin Medical Center ( Site 0043) Petah Tikva 4941492 Israel Details
Chaim Sheba Medical Center. ( Site 0044) Ramat Gan 5265601 Israel Details
Sourasky Medical Center ( Site 0041) Tel Aviv 6423906 Israel Details
National Cancer Center Hospital East ( Site 0400) Kashiwa Chiba 2778577 Japan Details
Japanese Foundation for Cancer Research ( Site 0401) Tokyo 135-8550 Japan Details
Severance Hospital Yonsei University Health System ( Site 0300) Seoul 03722 Korea, Republic of Details
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Warszawa Mazowieckie 02-781 Poland Details
Uniwersyteckie Centrum Kliniczne ( Site 0151) Gdansk Pomorskie 80-214 Poland Details
Wits Clinical Research ( Site 0213) Johannesburg Gauteng 2193 South Africa Details
The Oncology Centre ( Site 0212) Durban Kwazulu-Natal 4091 South Africa Details
Cancercare Rondebosch Oncology ( Site 0210) Cape Town Western Cape 7700 South Africa Details
Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0101) Hospitalet de Llobregat Barcelona 08908 Spain Details
Centro Integral Oncologico Clara Campal START Madrid ( Site 0102) Madrid 28050 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field